On World Tuberculosis Day, we raise our voices to increase awareness of the indication that is still one of the top ten causes of death worldwide and the leading cause of death from a single infectious agent. While curable and preventable, research is still needed to reduce tuberculosis (TB) incidence worldwide.

Research Breakthroughs and Clinical Trials Are Key

TB treatments have been used for decades, and strains that are resistant to one or more therapeutics have been documented worldwide. The evolution of the strains requires innovative breakthroughs in the prevention and treatment of the illness. Looking at the clinical trial landscape, we can see that at the moment there are 183 ongoing clinical trials on tuberculosis worldwide, 83 planned clinical studies on tuberculosis worldwide, and that the majority of studies are run in the Asia-Pacific and African regions, where TB incidence is highest.

At Cerba Research, we are committed to shaping patient’s lives. When it comes to battling TB, our experts and laboratories worldwide support drug and vaccine developers in their effort to reduce TB prevalence. Our strong presence in South Africa, one of the eight countries that account for two-thirds of new TB cases, highlights our commitment to lowering the global TB burden. 

P3 Labs and TB Testing

TB testing requires a P3 laboratory and, often, the use of GeneXpert machines, which have mainly been reallocated in 2020 as a global response to the COVID-19 pandemic. 

Our affiliate in South Africa, BARC SA, has one of the largest TB P3 laboratories in Africa, consisting of a P3 facility and a separate area for MGIT analyzers and microscopic analyses. This lab, combined with our network of laboratories in Europe and North America, has the testing capacity and capabilities needed to support TB clinical trials on an international scale. 

Furthermore, we understand the need to develop TB testing to support the research agenda of quantitative detection and further characterization (Targeted Next-Generation Sequencing for resistance detection, species determination [RFLP, TB Fingerprinting, whole-genome sequencing]) of TB.

Together, let’s lower the global tuberculosis burden.

Sources

  • World TB Day 2021. (2021, March 22). WHO. https://www.who.int/campaigns/world-tb-day/world-tb-day-2021
  • Global Data. (2021, March 22). Global Data. https://pharma.globaldata.com/ClinicalTrialsPartial/Search
  • WHO. (2020). Global Tuberculosis Report. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf

About Cerba Research

Cerba Research is the merge of Barc Lab, Histalim, and Cerba Xpert. All three entities are part of the Cerba HealthCare group and have decided to join forces under one name.

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Back to Blog